USD
$0.00
(0.00%
)At Close (As of Sep 3, 2025)
$1.91B
Market Cap
-
P/E Ratio
-3.56
EPS
$30.14
52 Week High
$8.24
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$43K |
Total Revenue | $0 |
Cost Of Revenue | $43K |
Costof Goods And Services Sold | $43K |
Operating Income | -$192M |
Selling General And Administrative | $24M |
Research And Development | $169M |
Operating Expenses | $192M |
Investment Income Net | - |
Net Interest Income | $15M |
Interest Income | $15M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $43K |
Income Before Tax | -$178M |
Income Tax Expense | -$178M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$178M |
Comprehensive Income Net Of Tax | - |
Ebit | -$192M |
Ebitda | -$192M |
Net Income | -$178M |
Field | Value (USD) |
---|---|
Total Assets | $206M |
Total Current Assets | $205M |
Cash And Cash Equivalents At Carrying Value | $114M |
Cash And Short Term Investments | $114M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $552K |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $0 |
Short Term Investments | $84M |
Other Current Assets | $7.2M |
Other Non Current Assets | - |
Total Liabilities | $15M |
Total Current Liabilities | $15M |
Current Accounts Payable | $479K |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $0 |
Capital Lease Obligations | - |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $14M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $191M |
Treasury Stock | - |
Retained Earnings | -$303M |
Common Stock | $5K |
Common Stock Shares Outstanding | $49M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$166M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $43K |
Capital Expenditures | $96K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | $115M |
Cashflow From Financing | $116M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $221K |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$178M |
Field | Value (USD) |
---|---|
Gross Profit | -$43K |
Total Revenue | $0 |
Cost Of Revenue | $43K |
Costof Goods And Services Sold | $43K |
Operating Income | -$192M |
Selling General And Administrative | $24M |
Research And Development | $169M |
Operating Expenses | $192M |
Investment Income Net | - |
Net Interest Income | $15M |
Interest Income | $15M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $43K |
Income Before Tax | -$178M |
Income Tax Expense | -$178M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$178M |
Comprehensive Income Net Of Tax | - |
Ebit | -$192M |
Ebitda | -$192M |
Net Income | -$178M |
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.